Amarin (AMRN) Is 'In Play'
Tweet Send to a Friend
Get Alerts AMRN Hot Sheet
Down)
Trade AMRN Now!
Shares of Amarin Corporation plc (Nasdaq: AMRN) are higher early Friday as traders get the memo that the stock is "in play," on likely Vascepa NCE approval and then a potential buyout.
Reports after the close Thursday suggested that NCE approval is 'in the bag.' If this is true, attention will turn to the product launch. The company could go it alone, partner with someone, or sell the entire operation.
Recently, analysts at MKM's Partners have been clamoring that a buyout is likely and could come before the end of the year. They said AstraZeneca (NYSE: AZN) is the most logical suitor, but Pfizer, Bristol Myers, Sanofi and others could also be interested.
Shares of AMRN are up 5 percent today to $12.85.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Reports after the close Thursday suggested that NCE approval is 'in the bag.' If this is true, attention will turn to the product launch. The company could go it alone, partner with someone, or sell the entire operation.
Recently, analysts at MKM's Partners have been clamoring that a buyout is likely and could come before the end of the year. They said AstraZeneca (NYSE: AZN) is the most logical suitor, but Pfizer, Bristol Myers, Sanofi and others could also be interested.
Shares of AMRN are up 5 percent today to $12.85.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Yahoo! (YHOO) Board Said to Approve $1.1B Tumblr Deal
- Shorts Buried in MLM Companies (HLF) (USNA) (NUS)
- Investors Brace for Epic Herbalife (HLF) Short Squeeze
Create E-mail Alert Related Categories
Insiders' Blog, Momentum Movers, Rumors
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
